![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, June 26, 2021 10:21:59 PM
I didn't see this posted yet, Tom seems positive!
https://www.moneyshow.com/articles/tptp2021-56851/
"Tom Bishop specializes in uncovering under-the-radar opportunities in small cap stocks. His Top Pick for 2021, Anavex (AVXL), is up 400% so far this year, making this the #1 performing stock out of 122 investment ideas in our 2021 Top Picks report. Here's a mid-year update on the stock from the editor of BI Research.
Anavex's lead compound Anavex 2-73 (A2-73, oral) is in clinical trials for Alzheimer’s disease (just finished over-enrollment of a phase 2b/3, 450-patient, 48-week clinical trial after very encouraging long term results from the phase 2a trial, see graphic below); Parkinson’s disease dementia (just finished a successful Phase 2 trial, also supportive for Alzheimer’s, with more data due out shortly); and Rett syndrome (for which it has three Rett trials in various stages with encouraging clinical data so far, and more due out shortly).
Encouragingly, A2-73 with its upstream Sigma-1 receptor activation approach (rather than anti-amyloid plaque approach that has failed so often) has consistently demonstrated positive and statistically significant results across this wide range of neurological diseases, which indicates that the oral drug appears to work and is clearly able to cross the blood/brain barrier.
“Data suggests [and numerous articles in medical journals confirm, for example see the Anavex press release dated 6/14] that activation of SIGMAR1 results in the restoration of complete housekeeping function within the body and is pivotal to restoring neural cell homeostasis and promoting neuroplasticity.”
In other words, Sigma-1 works further upstream from the problem and can be likened to the brain’s janitor, which in his later years gets lazy and doesn’t clean up the amyloid plaque and such that can clog the brain. It’s called autophagy — “the body's way of cleaning out damaged cells, in order to regenerate newer, healthier cells.”
Anavex 2-73 activates the janitor to get out there and keep up with his house cleaning. In addition, through genomic analysis the Company has identified a biomarker that 80% of people have which when present increases the efficacy of A2-73 vs. the other 20%.
While Rett may get to the finish line first due to shorter trial periods, Alzheimer’s is the most exciting indication based on the magnitude of this unmet medical need and the data so far.
For just one example, from the extended phase 2a trial based on patients on the high dose of A2-73, that have continued to take the drug for at least three years, they saw almost no decline in MMSE and ADL scores, while those on the lower dose (which essentially acted as a placebo because it hardly worked at that dosage) saw the decline in scores that Alzheimer’s patients typically see (the red line).
But a graph is worth a thousand words (note that the p-values are extraordinarily significant, where <=0.05 is considered significant by the FDA).
anavex
There is plenty of anecdotal evidence as well — an artist who was able to return to painting, a guy who was able to play golf again, the pianist who resumed playing and the grumpy couch potato who started playing with his grandkids again and even went into a TV station to give a very lucid and even humorous interview. And at the end of the day, these are the real life results you really want to see.
An estimated 5.8 million Americans (and 50 million worldwide) currently suffer with Alzheimer’s disease which along with other dementias cost our nation an estimated $305 billion in 2020. Alzheimer’s is the third leading cause of death in the U.S. behind heart disease and cancer and the only one of the top 6 diseases in the U.S. where the death rate has risen, rather than declined.
As demonstrated by the instant $20 billion increase in the market cap of Biogen on the FDA’s controversial approval of its Alzheimer’s monthly infusion therapy drug on 6/7 (for which efficacy was so poor that most doubted the FDA would even approve it), a drug that works on Alzheimer’s is clearly a holy grail of medicine.
This also demonstrated how desperate patients, and ergo the FDA, were to get anything approved that might help these patients after nothing new was approved in almost 20 years. This approval was actually good news for Anavex because it indicates a lowering of the bar for approval.
And based on data so far investors believe A2-73 will be able to show much greater efficacy in any event, plus … A2-73 is an oral drug, so patients would likely flock to it, leaving Biogen’s monthly infusion therapy … a buggy whip.
As positive statistically significant data continues to come in from the various trials this year, the shares have almost quadrupled so far in 2021 to around $20. However, if $10 billion is a reasonable estimate for annual sales for an Alzheimer’s drug that actually works, and Anavex were to just trade at a very low 2 times sales (and Biogen’s recent $20 billion surge bears this out), and even assuming the share count rises another 42% to 100 million, this would equate to an AVXL share price of $200.
While more about the trial results can be found in a report we issued dated 3/10 (a link is at the bottom of our home page), one of my favorite more-anecdotal quotes is from an investigator involved in the ongoing Alzheimer’s trial who said simply, “It’s just so exciting to be part of a Alzheimer’s trial and to see what we are seeing in these patients.”
You see, Alzheimer’s patient scores only go in one direction (worse), but clearly they were seeing patients showing improvement or at least holding the line and that hasn’t happened in other Alzheimer’s trials.
That much they can tell without breaking the code. The company has a record $75 million in the bank, which along with inputs from parties financially helping to finance these trials, could last this frugal company for nearly 3 years.
Meanwhile, the CEO recently commented that Anavex is resisting any partnering interest and has retained 100% until it can demonstrate that A2-73 works and get fair value for its shareholders. Then I think big pharma is quite likely to swoop in. "
Recent AVXL News
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/12/2024 09:45:00 AM
- Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/09/2024 09:45:00 AM
- Anavex Life Sciences Corporation Class Action: The Gross Law Firm Reminds Anavex Life Sciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2024 - AVXL • PR Newswire (US) • 04/05/2024 09:45:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 04/02/2024 09:45:00 AM
- Lost Money on Anavex Life Sciences Corporation(AVXL)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 03/29/2024 09:45:00 AM
- Investors who lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 03/26/2024 09:45:00 AM
- Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM